Alliance for Clinical Trials in Oncology
The Alliance for Clinical Trials in Oncology, often referred to as the Alliance, is a leading organisation headquartered in the United States, dedicated to advancing cancer research through innovative clinical trials. Founded in 2000, the Alliance has made significant strides in the oncology field, uniting a network of academic and community-based institutions to enhance the quality and efficiency of cancer treatment. Operating primarily across the US, the Alliance focuses on conducting multi-institutional clinical trials that aim to improve patient outcomes and accelerate the development of new therapies. Its unique collaborative model fosters partnerships among researchers, healthcare providers, and patients, ensuring a comprehensive approach to cancer care. Notably, the Alliance has contributed to numerous groundbreaking studies, solidifying its position as a key player in the oncology research landscape.
DitchCarbon Score
How does Alliance for Clinical Trials in Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alliance for Clinical Trials in Oncology's score of 28 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alliance for Clinical Trials in Oncology's reported carbon emissions
In 2023, the Alliance for Clinical Trials in Oncology reported total carbon emissions of approximately 50,125,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were recorded at 0 kg CO2e, while Scope 2 emissions totalled about 59,000 kg CO2e. The majority of emissions stemmed from Scope 3, amounting to approximately 50,125,000 kg CO2e. This includes significant contributions from purchased goods and services (about 43,034,000 kg CO2e), business travel (approximately 1,014,000 kg CO2e), and employee commuting (around 376,000 kg CO2e). In 2022, the organisation's total emissions were about 47,973,000 kg CO2e, with Scope 1 emissions at 2,000 kg CO2e and Scope 2 emissions at 50,000 kg CO2e. The Scope 3 emissions for that year were similar in structure, indicating a consistent pattern in their carbon footprint. Despite these figures, the Alliance for Clinical Trials in Oncology has not publicly disclosed any specific reduction targets or initiatives aimed at decreasing their carbon emissions. Their commitment to addressing climate change remains unclear, as there are no documented reduction targets or climate pledges available. This lack of transparency highlights an opportunity for the organisation to enhance its climate strategy and engage in more robust sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,000 | - |
| Scope 2 | 50,000 | 00,000 |
| Scope 3 | 47,973,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alliance for Clinical Trials in Oncology is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
